Targeting the mTOR pathway in idiopathic multicentric Castleman disease

Area of Science:

• Hematology
• Immunology
• Rare Diseases

Background:

• Idiopathic multicentric Castleman disease (iMCD) is a rare hematologic disorder characterized by systemic inflammation and organ dysfunction.
• While IL-6 targeted therapies are effective for some patients, a subset exhibits resistance.
• The precise etiology of iMCD remains largely unknown.

Purpose of the Study:

• To investigate the underlying mechanisms in iMCD patients refractory to IL-6 blockade.
• To identify novel therapeutic targets for treatment-resistant iMCD.
• To explore a precision medicine strategy for managing rare hematologic diseases.

Main Methods:

• In-depth analysis of serum inflammatory markers in three iMCD patients resistant to IL-6 therapy.
• Assessment of the mechanistic target of rapamycin (mTOR) pathway.
• Treatment with sirolimus, an mTOR inhibitor.

Main Results:

• Activation of the mTOR pathway was identified in iMCD patients experiencing symptom flares despite IL-6 blockade.
• Treatment with sirolimus led to complete remission in all three evaluated patients.
• The findings highlight the role of the mTOR pathway in iMCD pathogenesis.

Conclusions:

• The mTOR pathway represents a potential therapeutic target for a subset of iMCD patients.
• Sirolimus demonstrated efficacy in inducing remission in treatment-refractory iMCD.
• This study supports a precision medicine approach for developing targeted therapies for rare diseases like iMCD.